Goldman Sachs, Pfizer fall premarket; Morgan Stanley, Coinbase rise
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
RBC Capital on Goldman Sachs (GS): 'remain best in class'
January 18, 2023 7:20 AM ESTRBC Capital analyst Gerard Cassidy reiterated a Sector Perform rating and $370.00 price target on Goldman Sachs (NYSE: GS).
The analyst comments "GS is one of the preeminent global investment banks but even with its leading position, market conditions negatively impacted nearly all of its... More
Pfizer (PFE) requires an expense reset for potential upside - Wells Fargo
January 17, 2023 9:57 AM ESTWells Fargo analyst Mohit Bansal downgraded shares of Pfizer (NYSE: PFE) to Equal Weight from Overweight, cutting the firm's price target on the stock to $50 from $54 per share in a note to clients on Tuesday.
Pfizer shares have declined more than 3%... More
